FDA recall, , Moderate risk
Innovative Blood Resources Red Blood Cells, Leukocytes Reduced
Red Blood Cells, Leukocytes Reduced were collected from a donor who previously tested reactive for Hepatitis B core antigen antibody.
Recall ended Sep 15, 2026. Still check yours.
Summary by Recall Canary from the FDA notice
What happened
Innovative Blood Resources recalled Red Blood Cells, Leukocytes Reduced because they were collected from a donor who previously tested reactive for the antibody to Hepatitis B core antigen (anti-HBc) on more than one occasion. The recall began May 14, 2025, and the FDA added it to its Enforcement Report on September 15, 2026. The product was distributed in Minnesota.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Compare these details with yours, then check the recall notice to see which units are recalled.
Red Blood Cells, Leukocytes Reduced
Recall details
- Company began the recall
- Sold in
- Company
- Innovative Blood Resources
- Hazard
- Blood donor screening
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 99599
- Recall number
- B-0180-2026
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA · Recall ended
In FDA's weekly enforcement report
Listed on Recall Canary
